The efficacy of trastuzumab was further assessed and predicted through the correlation of molecular imaging biomarkers of apoptosis, glucose metabolism, and cell proliferation and tumor regression, in responsive and nonresponsive tumor-bearing cohorts, in two mouse models of breast cancer overexpressing HER2. This evidence concerns the gene ERBB2 and breast carcinoma.